M M Morris1, S N Powell. 1. Department of Radiation Oncology, Massachusetts General Hospita, Harvard Medical School, Boston 02114, USA. morris@hadron.mgh.harvard.edu
Abstract
PURPOSE: Based on reports of greater toxicity from radiation therapy, collagen vascular diseases (CVDs) have been considered a contraindication to irradiation. We assessed the complications of radiation therapy in patients with CVD. PATIENTS AND METHODS: A total of 209 patients with documented CVD were irradiated between 1960 and 1995. One hundred thirty-one had rheumatoid arthritis (RA), 25 had systemic lupus erythematosus (SLE); 17 had polymyositis or dermatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had discoid lupus erythematosus; and four had 4 mixed connective tissue disorders (MCTD). The mean follow-up duration of curative cases was more than 6 years. Doses ranged from 10 to 87.6 Gy, with a median of 45 Gy. RESULTS: Overall, 263 sites were assessable in 209 patients. Significant (> or = grade 3) acute toxicity was seen in 10% of irradiated sites. Severe late effects were associated with significant acute reactions and with non-RA CVDs (6% v 21% at 5 years). No difference was seen in late effects according to timing of CVD onset, presence of concurrent vascular insults, radiation dose, or other technical factors, or by measures of disease activity. CONCLUSION: RA does not appear to have an elevated rate of late toxicity. While non-RA CVD is significantly associated with increased radiation late effects at standard doses, radiation-related mortality remains exceedingly rare. The choice of therapeutic modality in this radiosensitive group of patients should be made on a case-by-case basis.
PURPOSE: Based on reports of greater toxicity from radiation therapy, collagen vascular diseases (CVDs) have been considered a contraindication to irradiation. We assessed the complications of radiation therapy in patients with CVD. PATIENTS AND METHODS: A total of 209 patients with documented CVD were irradiated between 1960 and 1995. One hundred thirty-one had rheumatoid arthritis (RA), 25 had systemic lupus erythematosus (SLE); 17 had polymyositis or dermatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had discoid lupus erythematosus; and four had 4 mixed connective tissue disorders (MCTD). The mean follow-up duration of curative cases was more than 6 years. Doses ranged from 10 to 87.6 Gy, with a median of 45 Gy. RESULTS: Overall, 263 sites were assessable in 209 patients. Significant (> or = grade 3) acute toxicity was seen in 10% of irradiated sites. Severe late effects were associated with significant acute reactions and with non-RA CVDs (6% v 21% at 5 years). No difference was seen in late effects according to timing of CVD onset, presence of concurrent vascular insults, radiation dose, or other technical factors, or by measures of disease activity. CONCLUSION: RA does not appear to have an elevated rate of late toxicity. While non-RA CVD is significantly associated with increased radiation late effects at standard doses, radiation-related mortality remains exceedingly rare. The choice of therapeutic modality in this radiosensitive group of patients should be made on a case-by-case basis.
Authors: Dhaval J Shah; Ram Hirpara; Corrie L Poelman; Adrianne Woods; Laura K Hummers; Fredrick M Wigley; Jean L Wright; Arti Parekh; Virginia D Steen; Robyn T Domsic; Ami A Shah Journal: Arthritis Care Res (Hoboken) Date: 2018-10 Impact factor: 4.794
Authors: Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella Journal: Eur J Nucl Med Mol Imaging Date: 2005-03 Impact factor: 9.236
Authors: George Kyrgias; Kiki Theodorou; Anna Zygogianni; Konstantinos Tsanadis; Stefanos Zervoudis; John Tzitzikas; Michael Koukourakis Journal: Breast Cancer (Dove Med Press) Date: 2012-01-24
Authors: Ajaykumar B Patel; Christopher L Hallemeier; Ivy A Petersen; Ashley W Jensen; Thomas G Osborn; Robert C Miller Journal: Radiat Oncol Date: 2012-02-16 Impact factor: 3.481